ENDRA Life Sciences to Participate in Upcoming Investor and Industry Conferences

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS^®), announces that management will present a company overview at the H.C. Wainwright 24^th Annual Global Investment Conference being held September 12-14, 2022 in a virtual format and in-person in New York City and will be holding one-on-one meetings. A webcast of the presentation will be available on-demand beginning September 12, 2022 at 7:00 a.m. Eastern time on the Investors section of ENDRA’s website.

In addition, ENDRA will be participating in the following clinical industry conferences:

• EASL NAFLD Summit 2022
  
  European Association for the Study of the Liver
  
  September 15–17 in Dublin, Ireland
  
  https://easl.eu/event/easl-nafld-summit-2022/
• 2022 BASL Annual Meeting
  
  British Association for the Study of Liver
  
  September 20-23 in Leeds, United Kingdom
  
  https://www.basl.org.uk/
• 91èmes Journées Scientifiques de l’AFEF
  
  Société Française d’Hépatologie
  
  October 5-8 in Dijon, France
  
  https://www.congres-afef.com/
• AASLD The Liver Meeting
  
  American Association for the Study of Liver Disease
  
  November 4-8 in Washington D.C., U.S.
  
  https://www.aasld.org/the-liver-meeting

“We look forward to attending these clinical conferences in person to drive further awareness of our TAEUS system globally. These conferences provide excellent opportunities to demonstrate our TAEUS system’s clinical utility and to stay abreast of key clinical and technology trends,” stated ENDRA's Chief Commercial Officer, Renaud Maloberti. “Importantly, our sales team continues to build a substantial number of sales leads in high-value clinical segments, which we look forward to converting to sales as our base of clinical evidence grows.”

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50^th the cost and at the point of patient care. TAEUS^® is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” "anticipate," “attempt,” "believe," "could," "estimate," "expect," “forecast,” “future,” "goal," “hope,” "intend," "may," "plan," “possible,” “potential,” “project,” "seek," "should," "will," “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing for receipt of required regulatory approvals and product launches; future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; ENDRA’s ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; and ENDRA’s ability to protect its intellectual property. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA’s business plans; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005148/en/